Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2018-05-21 11:09 UTC (UTC+2h)
 

Sample Size Estimation -Replicate design- BE limits [Power / Sample Size]

posted by cakhatri - India, 2017-11-30 08:44  - Posting: # 18024
Views: 4,158

Dear All,

I would like to know

1.What BE limits should be taken into consideration while estimating sample size for replicate design studies for USFDA & EMA.

Should it be 80-125% ? We normally use FARTSSIE

Why the Question

1. For a product with 51% ISCV (from a completed partial replicate study UKMHRA) by using FARTSSIE we arrived at different sample size for EMA

- Sample size estimated =27 (80% Power, 95-105% T/R, Method C1, BE Limits 69.84 to 143.19%)
- Sample size estimated = 76 (80% Power,95-105% T/R, No reference Scaled BE Limits-80-125%)

Which sample size should we consider for pivotal study

Regards
Chirag

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
18,269 posts in 3,882 threads, 1,161 registered users;
14 users online (1 registered, 13 guests).

Science is wonderfully equipped to answer the question “How?”
but it gets terribly confused when you ask the question “Why?”    Erwin Chargaff

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed